Name Ingredients:
Pyrilutamide, also known as KX-826, is an androgen receptor antagonist developed for treating androgenetic alopecia and acne vulgaris. While press releases have given insights into the potential efficacy of this topical treatment, there is currently no peer-reviewed published data.
Key insights:
- There do not appear to be any in vitro or in vivo studies supporting its use as a hair loss treatment.
- The only clinical data available is from press releases:
- In China, a 24-week trial was conducted on 160 women with female-pattern hair loss. The 0.5% once-daily treatment showed the best results. In another trial on 120 men with male-pattern hair loss, the 0.5% twice-daily treatment was the most effective. A phase 1 trial on 40 men in the US showed that pyrilutamide treatment had low risk and only caused mild contact dermatitis. A Phase 3 trial for male AGA in China, has found that there was no statistically significant increase in hair growth compared to the placebo.
- Our experience tracking members: pyrilutamide alone is not enough to improve hair loss outcomes.
Additional links:
- Pyrilutamide: Evidence Quality (Rubric)
- Kintor Pharma Announced the Primary Endpoint of Phase II Clinical Study for KX-826's Treatment of Female Androgenetic Alopecia in China Was Met
- Kintor Pharma Announces Completion of Subject Enrollment in Phase III Clinical Trial of KX-826 for Treatment of Male Androgenetic Alopecia in China
- Results Of KX-826 Phase III clinical trial for treatment of male AGA in China